DenmarkDKK 266.10+2.21%
Click any ratio for an explanation.
Revenue grew +21.7% a year over the last 4 fiscal years, fast for a listed company. Profit per share moved in step at +22.0% a year. Analysts expect profit to fall back next year, since the forward multiple sits above the trailing one.
| Ratio | Value | Weak → Strong | Score | Wt |
|---|---|---|---|---|
| +22.0% | -5% → +20% | 100 | 40% | |
| +21.7% | -2% → +15% | 100 | 35% | |
| -15.2% | -10% → +30% | 0 | 25% |
The share is down over every window (-9.0% in 3 months, -8.0% in 6, -12.1% in 12), a persistent downtrend. Recent months are weaker than the longer window, so momentum is fading.
| Ratio | Value | Weak → Strong | Score | Wt |
|---|---|---|---|---|
| -9.0% | -20% → +20% | 28 | 35% | |
| -8.0% | -25% → +30% | 31 | 30% | |
| -12.1% | -30% → +45% | 24 | 35% |
Net debt is only 0.55x EBITDA, comfortably repayable out of ordinary earnings. Debt at 63% of equity is a normal level of leverage.
| Ratio | Value | Weak → Strong | Score | Wt |
|---|---|---|---|---|
| 0.5x | 3.5x → -1.0x | 66 | 30% | |
| 63% | 200% → 10% | 72 | 20% | |
| 18.7% | 0% → 15% | 100 | 15% | |
| 0.8 | 0.8x → 2.0x | 0 | 10% | |
| 5/9 | 3/9 → 8/9 | 40 | 10% | |
| 3.8 | 1.8 → 5.0 | 63 | 10% | |
| 19.9x | 2x → 20x | 99 | 5% |
Return on equity of 59.8% means the company earns far more on its capital than it costs to fund. About 35% of every euro of revenue survives as net profit, which points to real pricing power. ROIC of 35.5% confirms the returns are not just an effect of leverage.
| Ratio | Value | Weak → Strong | Score | Wt |
|---|---|---|---|---|
| 59.8% | 5% → 35% | 100 | 30% | |
| 42.5% | 3% → 30% | 100 | 25% | |
| 35.3% | 2% → 25% | 100 | 20% | |
| 35.5% | 4% → 20% | 100 | 15% | |
| 81.0% | 15% → 60% | 100 | 10% |
At 10.2x trailing earnings the share is cheap against the market. The forward P/E of 12 is higher than the trailing one, so next year's expected profit makes it look dearer. EV/EBITDA of 7.3 confirms the cheap reading including debt. A dividend yield of 4.4% adds to the return while you wait. Based on 75% of the inputs — the rest is not published for this instrument.
| Ratio | Value | Weak → Strong | Score | Wt |
|---|---|---|---|---|
| 10.2x | 40x → 8x | 93 | 30% | |
| 12x | 32x → 7x | 80 | 20% | |
| 7.3x | 22x → 6x | 92 | 15% | |
| 4.40% | 0% → 6% | 73 | 10% | |
| n/a | 1.6x → 0.7x | — | 25% |
Annualised volatility of 41.7% means large swings are routine here. The worst fall in the past year was -35.6%, so drawdowns can be painful. A beta of 0.38 means it typically moves less than the market.
| Ratio | Value | Weak → Strong | Score | Wt |
|---|---|---|---|---|
| 41.7% | 55% → 15% | 33 | 40% | |
| -35.6% | -40% → -8% | 14 | 35% | |
| 0.38 | 1.8 → 0.7 | 100 | 25% |
Source: Yahoo Finance + EODHD
Last 5 fiscal years plus the current year. Click any row for an explanation.
Recent analyst views
Loading analyst views…
Recent analyst actions
No individual broker rating actions are published for this instrument.
- Mean target
- DKK 297.24
- Target range
- DKK 203.00 – DKK 445.00
- Implied upside
- +11.7%
- Consensus score
- 3.04
Quarterly results · 4 Nov 2026
Reports after market close · consensus EPS 4.89
Dividend
Forward annual dividend 11.7 DKK; last ex-dividend 2026-08-14. Next date not yet published
Investor day
Checking public announcements…
Mergers & acquisitions
Checking public announcements…
Loading headlines…
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Plus, smart insulin pens; Dose Check, an insulin dose guidance application; growth hormone pens and injection needles; and Wegovy pill an oral glucagon-like peptide-1 (GLP-1) receptor agonist therapy for weight management. The company has a collaboration with Anthropic accelerate the development of new medicines and advance AI-driven software development. It operates in Europe, Canada, the United States, Japan, Korea, Oceania, Southeast Asia, Mainland China, Hong Kong and Taiwan, Latin America, the Middle East, and Africa. It has a strategic collaboration with Orbis Medicines to discover and develop oral macrocycle therapeutics for cardiometabolic diseases. The company was formerly known as Novo Industri A/S and changed its name to Novo Nordisk A/S in April 1989. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
novonordisk.com